Efficacy, safety, and tolerability of arbaclofen in Autistic children and adolescents, the AIMS-2-TRIALS-CT1: a randomized, double-blind, placebo-controlled phase II trial

Alternative Title

Abstract

Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394.

Description

Citation

Parellada, M. et al. (2026) ‘Efficacy, safety, and tolerability of arbaclofen in Autistic children and adolescents, the AIMS-2-TRIALS-CT1: a randomized, double-blind, placebo-controlled phase II trial’, eClinicalMedicine, 92, p. 103760. Available at: https://doi.org/10.1016/j.eclinm.2026.103760.

Publisher

License

Journal

EClinicalMedicine

Volume

92

Issue

PubMed ID

DOI

ISSN

EISSN